Ki-1 large cell lymphoma: A clinical study of 12 cases.
The treatment and prognosis of Ki-1 positive lymphoma, a relatively new entity, remains largely unknown and the clinical features are still being defined. This is a retrospective analysis of our experience with 12 patients with Ki-1 lymphoma who were treated at our hospital over two years. Clinical presentation and management are described and an attempt is made to identify prognostic factors. The median age at presentation was 20 and the male/female ratio 1:1. Nine patients presented with nodal disease and three with extranodal. B symptoms were present in seven patients. Seven patients had stage I/II disease and five had stage IV. Immunophenotyping was available in 10 patients of which five were T-cell, two B-cell, and two null cell; one could not be categorized. All 12 patients received combination chemotherapy; five had consolidation radiotherapy. With a median follow-up of 11 months (range one to 29), actuarial survival was 67% at 29 months and disease-free survival 50% for all patients. Five out of seven patients with stage I/II and one out of five with stage IV remain disease free. We conclude that the clinical presentation is diverse and advanced stage appears to be the only identifiable adverse prognostic factor.